Form 4: iBio CFO Felipe Duran Granted Stock Options

Felipe Duran, CFO of iBio, Inc., was granted stock options to purchase 90,000 shares of common stock on May 9, 2024.

Summary

• On May 9, 2024, Felipe Duran, the Chief Financial Officer of iBio, Inc., was granted stock options.
• These options allow Duran to purchase 90,000 shares of iBio's common stock at an exercise price of $1.88 per share.
• The options vest in equal quarterly installments over a 36-month period, starting from the grant date.
• The options expire on May 9, 2034.

Sentiment

Score: 7

Explanation: The granting of stock options is generally viewed positively as it aligns management's interests with shareholders, but it also represents potential future dilution.

Positives

• The granting of stock options to the CFO aligns his interests with those of the shareholders, incentivizing him to improve the company's performance.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize executives and align their interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the biotech industry.
• Companies like Moderna and BioNTech also utilize stock options to incentivize their leadership teams.
• The vesting schedule of quarterly installments over 36 months is a standard practice.

Stakeholder Impact

• Shareholders may experience dilution if the options are exercised.
• Employees may view the option grant as a positive sign of the company's commitment to its leadership.

Key Dates